KCRS24 Presentations & Video
Program content is now LIVE! View the program presentations, including video and slides, using the interactive program below. Each video is the full session length; to jump to a particular presentation, note the timestamp in red beneath the speaker’s name.Â
To view slide presentations, click the icon or presentation title.
Thursday, July 11th
How the Air We Breathe Can Impact Cancer
Keynote: Charles Swanton, The Francis Crick Institute
View slides
Session 1: Exploring Novel Drug Targets for RCC
Moderated by Pavlos Msaouel, MD Anderson Cancer Center & Scott Tykodi, Fred Hutchinson Cancer Center
Purinergic Receptor Antagonist Therapeutics in Treating Metastatic Renal Cancer
Jean Jiang, University of Texas Health San Antonio
(Video presentation begins at 1:58)
Identification of Novel Therapeutic Strategies for Chromophobe RCC
Elizabeth Henske, Brigham & Women’s Hospital/Harvard Medical School
(Video presentation begins at 13:27)
Interrogating the Therapeutic Relevance of Targeting The Antiapoptotic BCL-XL Protein in Kidney Cancer
Abhishek Chakraborty, Cleveland Clinic Foundation
(Video presentation begins at 27:50)
SETD2 Deficiency is a Therapeutic Target to Upregulate Viral Mimicry in Treating Aggressive Clear Cell Renal Cell Carcinoma Patient
Neil Bhowmick, Cedars-Sinai Medical Center
(Video presentation begins at 40:50)
Session 2: Novel Imaging and Biomarkers to Guide RCC Patient Management
Moderated by Katy Beckermann, Vanderbilt University Medical Center & Stephanie Berg, Dana-Farber Cancer Institute
PET Imaging of HIF-2a in Renal Cancer
Xiankai Sun, University of Texas Southwestern Medical CenterNeil Bhowmick, Cedars-Sinai Medical Center
(Video presentation begins at 1:44)
Multiplexed Quantification of Urinary Biomarkers for Noninvasive Classification of Imaged Kidney Tumors
Jeremiah Morrissey, Washington University in St. Louis
(Video presentation begins at 16:36)
Multimodal AI-Based Renal Cancer Patient Care
Christopher Weight, Cleveland Clinic Foundation
(Video presentation begins at 29:20)
Shared Heritability Between Renal Cell Carcinoma and Hematopoietic-Related Phenotype
Valisha Shah, Dana-Farber Cancer Institute
(Video presentation begins at 49:06)
Session 3: State of the Science
Moderated by Rohit Mehra, University of Michigan & Payal Kapur, University of Texas Southwestern Medical Center
Taxonomic Evolution of Kidney Cancer with Emphasis on Molecularly Defined RCC
Samson Fine, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 02:00)
Surgical Pathology Toolbox and Technological Advances to Solve Kidney Cancer Problems
Michelle Hirsch, Brigham & Women’s Hospital
(Video presentation begins at 14:31)
Prognostic and Predictive Biomarkers in Kidney Cancer
Payal Kapur, University of Texas Southwestern Medical Center
(Video presentation begins at 26:13)
Sarcomatoid Renal Cell Carcinoma: Diagnostic Updates and Therapeutic Implications
Sabina Signoretti, Brigham and Women’s Hospital
(Video presentation begins at 35:53)
Role of Pathologist in Kidney Cancer Diagnostics and Research
Rohit Mehra, University of Michigan
(Video presentation begins at 47:02)
Session 4: Trials in Progress
Moderated by Robert Motzer, Memorial Sloan Kettering Cancer Center & Naomi Haas, Abramson Cancer Center/University of Pennsylvania
Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)
Michael Serzan, Dana-Farber Cancer Institute
(Video presentation begins at 01:06)
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
Rana McKay, University of California, San Diego
(Video presentation begins at 06:47)
Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma
Pavlos Msaouel, MD Anderson Cancer Center
(Video presentation begins at 10:43)
Pilot Study of an Implantable Microdevice for In Vivo Evaluation of Drug Response in Renal Cell Carcinoma (NCT05700461)
Clara Steiner, Dana-Farber Cancer Institute
(Video presentation begins at 16:22)
INTerpath-004: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab with V940 (mRNA-4157) or Placebo in the Adjuvant Treatment of Renal Cell Carcinoma
Toni Choueiri, Dana-Farber Cancer Institute
(Video presentation begins at 19:27)
WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer
Grant Stewart, University of Cambridge
(Video presentation begins at 24:09)
Friday, July 12th
Obesity and Immunotherapy
Featured Speaker: Jeffrey Rathmell, Vanderbilt University Medical Center
Friday, July 12th
Session 5: Clinical and Scientific Updates in Kidney Cancer
Moderated by Toni Choueiri, Dana-Farber Cancer Institute
Front Line Systemic Therapy Strategies
Tom Powles, Barts Cancer Centre
(Video presentation begins at 00:59)
Subsequent Line Treatments for Advanced Disease
Robert Motzer, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 13:44)
Adjuvant Treatment Options
Bradley McGregor, Dana-Farber Cancer Institute
(Video presentation begins at 28:13)
Strategies for Patients with Non-Clear Cell RCC
Laurence Albiges, Institut Gustave-Roussy
(Video presentation begins at 37:49)
Novel Therapies Outside Immunotherapy
Rana McKay, University of California, San Diego
(Video presentation begins at 48:46)
Novel Immunotherapy Strategies
David Braun, Yale Cancer Center
(Video presentation begins at 1:01:55)
Session 6: Immunotherapy Advances and Research
Moderated by Hans Hammers, UT Southwestern Medical Center &
David McDermott, Beth Israel Deaconness
Overview in Development of Immunotherapy for Kidney Cancer
Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center
(Video presentation begins at 02:10)
Mechanisms and Predictors of Adoptive Cytokine-Induced Memorylike NK Cell Therapy in Renal Cell Carcinoma
Rizwan Romee, Dana-Farber Cancer Institute
(Video presentation begins at 16:43)
Delineate Tumor-Immune Contexture That Shapes ccRCC Metastatic Progression and Response to Immunotherapy
Srinivas Malladi, University of Texas Southwestern Medical Center
(Video presentation begins at 36:45)
Consortium Clinical Trial and the Mechanisms and Preclinical Research
Jonathan Powell, Calico Labs
(Video presentation begins at 47:30)
Uncovering the Tumor-Immune Microenvironmental Determinants of Immunotherapy Response in Renal Cell Carcinoma Through Ex Vivo Patient-Derived Models
David Braun, Yale School of Medicine
(Video presentation begins at 1:00:04)
Session 7: Oral Abstract Presentations
Moderated by Rana McKay, University of California, San Diego &
Yuksel Urun, Ankara University School of Medicine
Belzutifan Versus Everolimus for Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 LITESPARK-005 Study
Laurence Albiges, Institut Gustave-Roussy
(Video presentation begins at 01:46)
Safety Profile of Belzutifan Monotherapy in Patients with Renal Cell Carcinoma: A Pooled Analysis of 4 Clinical Trials
Toni Choueiri, Dana-Farber Cancer Institute
(Video presentation begins at 09:17)
CDK4/6 Inhibition with Abemaciclib in Patients (pts) With Previously Treated Advanced Renal Carcinoma (RCC)
Bradley McGregor, Dana-Farber Cancer Institute
(Video presentation begins at 17:13)
Association of a Germline Single Nucleotide Polymorphism (SNP) in the Interleukin-7 (IL7) Gene with Immune-Related Adverse Events (irAEs)
Eddy Saad, Dana-Farber Cancer Institute
(Video presentation begins at 39:26)
Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid Renal Cell Carcinoma
Karl Semaan, Dana-Farber Cancer Institute
(Video presentation begins at 46:42)
Impact of CBM588 on Gut Microbiome Composition and Dysbiosis in Patients Receiving Frontline Immune Checkpoint Inhibitor (ICI) Combinations for Metastatic Renal Cell Carcinoma (mRCC)
Nazli Dizman, MD Anderson Cancer Center
(Video presentation begins at 53:01)
Session 8: Rapid Abstract Presentations
Moderated by Thomas Powles, Bart Cancer Centre &
Evita Sadimin, City of Hope Comprehensive Cancer Center
Enrichment of Tertiary Lymphoid Structures Provides Novel Insight into Mediators of Anti-Tumor Immune Activity in Sarcomatoid Renal Cell Carcinoma
Nicholas Salgia, Roswell Park Comprehensive Cancer Center
(Video presentation begins at 02:43)
Tumor Evolution of Brain-Specific Tropism in Metastatic Renal Cell Carcinoma
Roy Elias, Johns Hopkins
(Video presentation begins at 07:40)
Impact of Latino Ethnicity on the Gut Microbiome Composition of Patients with Metastatic Renal Cell Cancer (mRCC)
Regina Barragan-Carrillo, City of Hope Comprehensive Cancer Center
(Video presentation begins at 11:37)
Natural Killer Cells Have Impaired Cytotoxicity in Advanced Renal Cell Carcinoma
Vivien Moritz, Yale School of Medicine
(Video presentation begins at 22:52)
Development of an Ex Vivo Patient-Derived Tumor Model (PDTM) to Assess the Tumor Microenvironment in Renal Cell Carcinoma (RCC)
Soki Kashima, Yale School of Medicine
(Video presentation begins at 27:01)
Fasting Mediated Gut Microbiome Modulation Improves Response to Immune Checkpoint Therapy in Renal Cell Cancer
Shahla Bari, Duke University
(Video presentation begins at 31:34)
Ferroptosis Suppressor Protein 1 is a Potent and Targetable Inhibitor of Ferroptosis in Chromophobe Renal Cell
Samer Salem, Brigham and Women’s Hospital
(Video presentation begins at 37:15)
Concordance Analysis of Tissue and Circulating Tumor DNA (ctDNA) in Renal Cell Carcinoma (RCC): Insights from a Multimodal Real-World Database
Chinmay Jani, Sylvester Comprehensive Cancer Center
(Video presentation begins at 47:55)
Evaluating Intermediate Endpoints for Overall Survival in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: An IMDC Study
Renee Maria Saliby, Dana-Farber Cancer Institute
(Video presentation begins at 52:25)
A Phase 1 Study of Fianlimab (Anti–LAG-3) in Combination With Cemiplimab (Anti–PD-1) in Patients with Advanced ccRCC
Miso Kim, Seoul National University Hospital
(Video presentation begins at 56:47)
Special Session: Biotech Showcase
Sumanta Pal, City of Hope Comprehensive Cancer Center &
Hans Hammers, UT Southwestern Medical Center
Casdatifan (AB521): A Hif-2-alpha Inhibitor in Development for ccRCC
Dimitry Nuyten, Arcus Biosciences
(Video presentation begins at 02:10)
Phase 1 Study Results of SRK-181 (Linavonkibart), A Latent TGFβ1 Inhibitor, Combined with Pembrolizumab in Anti-PD1 Resistant ccRCC Patients
Lu Gan, Scholar Rock
(Video presentation begins at 09:29)
STK-012, a First-in-Class α/β IL-2 Receptor Biased Partial Agonist in Advanced Solid Tumors
Alex Azrilevich, Synthekine, Inc.
(Video presentation begins at 16:54)
819-01 Study: A Novel Bispecific Antibody Targeting ENPP3 in ccRCC
Chet Bohac, Xencor
(Video presentation begins at 26:37)
AB-2100: A Novel Investigational Cell Therapy for Clear Cell Renal Cell Carcinoma
Levi Gray-Rupp, ArsenalBio
(Video presentation begins at 31:50)
Comprehensive Genomic and Transcriptomic Profiling to Identify Distinct Therapeutic Targets for Renal Cell Carcinoma Subtypes: The Renal Medullary Carcinoma Paradigm
Pavlos Msaouel, BostonGene, Principal Investigator
(Video presentation begins at 56:13)
Emerging Therapies in RCC: A Precision Theranostic Approach
Kim Allman, Telix
(Video presentation begins at 1:06:44)
